Penumbra secures FDA clearance for stroke thrombectomy system

AuntMinnie.com staff writers

Jun 12, 2026

Penumbra has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Thunderbolt, a computer-assisted vacuum thrombectomy system for acute ischemic stroke.

Thunderbolt introduces modulated aspiration to the company's neuro thrombectomy portfolio. The system is designed to detect, loosen, and remove clots at the site of occlusion, according to the company. Penumbra said Thunderbolt is the first such system to deliver modulated aspiration for stroke.

Modulated aspiration may facilitate more consistent and complete clot removal when used in conjunction with standard aspiration thrombectomy catheters, according to the company. The system will be prepackaged with one of four of Penumbra’s RED catheters, Penumbra noted.

Preablation, postablation, and recurrence multiparametric MRI scans depict a 63-year-old man treated with transperineal focal laser ablation (TPLA) for localized prostate cancer. Clinical parameters included an initial prostate-specific antigen (PSA) level of 7.2 ng/mL, a Prostate Imaging Reporting and Data System (PI-RADS) grade 4 lesion (red circles) in the right apical peripheral zone, and a maximum tumor length of 5 mm. MRI-guided targeted biopsy confirmed a Gleason score 3+4 prostate cancer tumor. (A) Pre-ablation axial T2-weighted MRI scan and apparent diffusion coefficient (ADC) image shows the apical PI-RADS 4 lesion (circles). (B) Six-month post-ablation axial T2-weighted MRI scan and ADC image show cystic necrosis (arrows). There was no evidence of recurrence; the PSA level was 1.5 ng/mL. (C) One-year after ablation, the patient’s PSA level had increased to 4.3 ng/mL. Axial T2-weighted MRI scan and the ADC image shows a recurrent lesion (blue circles) in the right apical peripheral zone adjacent to the ablation scar. Targeted biopsy confirmed Gleason score 3+4 prostate cancer, which was classified as in-field recurrence of clinically significant prostate cancer and subsequently re-treated with TPLA. In summary, serial multiplanar MRI demonstrates treatment response after TPLA with post-ablation necrosis, followed by MRI-detected IFR confirmed with biopsy at 12-month follow-up. Multiparametric MRI was performed with a 3.0-T MRI scanner (Skyra; Siemens Healthineers) using T2-weighted, diffusion-weighted, and ADC sequences, with gadobenate dimeglumine contrast material administration (Bracco Diagnostics).

Image-guided focal laser ablation effective for prostate cancer

June 3, 2026

IR role-specific radiation study suggests reducing apron thickness

May 22, 2026

A 44-year-old woman with TFCC injury treated by transcatheter arterial embolization (TAE). a) Right brachial arteriography via common femoral artery access with a 5-Fr catheter demonstrates hyperstaining on the ulnar side of the wrist joint (white circle). b) An ulnar artery branch is superselected with a 1.9-Fr microcatheter, showing hypervascular staining corresponding to the pain site (white arrow). c) Delayed-phase angiography reveals early venous drainage (white arrow) adjacent to the hyperstaining, a finding often observed in TAE and considered an additional marker for embolization. d) Final angiography after injection of 0.5 mL quick-soluble gelatin sponge particles (QS-GSPs) demonstrates resolution of the hyperstaining (white circle). The VAS pain score improved from 7 at baseline to 1 at six months.

TAE reduces pain in patients with chronic wrist pain

May 20, 2026

The combination of Syngo.CT Coronary Cockpit and Syngo PCI Connect gives interventional cardiologists valuable insights on morphology, plaque and lesion details and allows for strategic planning of the intervention.

Siemens unveils CT-guided PCI workflow system

May 19, 2026

Image-guided focal laser ablation effective for prostate cancer

By Amerigo Allegretto

MRI-directed, ultrasound-guided TPLA may be a promising technique to treat prostate cancer while avoiding radical therapies.

June 3, 2026

Preablation, postablation, and recurrence multiparametric MRI scans depict a 63-year-old man treated with transperineal focal laser ablation (TPLA) for localized prostate cancer. Clinical parameters included an initial prostate-specific antigen (PSA) level of 7.2 ng/mL, a Prostate Imaging Reporting and Data System (PI-RADS) grade 4 lesion (red circles) in the right apical peripheral zone, and a maximum tumor length of 5 mm. MRI-guided targeted biopsy confirmed a Gleason score 3+4 prostate cancer tumor. (A) Pre-ablation axial T2-weighted MRI scan and apparent diffusion coefficient (ADC) image shows the apical PI-RADS 4 lesion (circles). (B) Six-month post-ablation axial T2-weighted MRI scan and ADC image show cystic necrosis (arrows). There was no evidence of recurrence; the PSA level was 1.5 ng/mL. (C) One-year after ablation, the patient’s PSA level had increased to 4.3 ng/mL. Axial T2-weighted MRI scan and the ADC image shows a recurrent lesion (blue circles) in the right apical peripheral zone adjacent to the ablation scar. Targeted biopsy confirmed Gleason score 3+4 prostate cancer, which was classified as in-field recurrence of clinically significant prostate cancer and subsequently re-treated with TPLA. In summary, serial multiplanar MRI demonstrates treatment response after TPLA with post-ablation necrosis, followed by MRI-detected IFR confirmed with biopsy at 12-month follow-up. Multiparametric MRI was performed with a 3.0-T MRI scanner (Skyra; Siemens Healthineers) using T2-weighted, diffusion-weighted, and ADC sequences, with gadobenate dimeglumine contrast material administration (Bracco Diagnostics).

IR role-specific radiation study suggests reducing apron thickness

Thinner aprons for interventional radiology personnel may reduce risk of musculoskeletal disorders without compromising radiation safety.

May 22, 2026

TAE reduces pain in patients with chronic wrist pain

The finding suggests that the emerging interventional radiology procedure could be a new option for patients who have exhausted conservative management.

May 20, 2026

A 44-year-old woman with TFCC injury treated by transcatheter arterial embolization (TAE). a) Right brachial arteriography via common femoral artery access with a 5-Fr catheter demonstrates hyperstaining on the ulnar side of the wrist joint (white circle). b) An ulnar artery branch is superselected with a 1.9-Fr microcatheter, showing hypervascular staining corresponding to the pain site (white arrow). c) Delayed-phase angiography reveals early venous drainage (white arrow) adjacent to the hyperstaining, a finding often observed in TAE and considered an additional marker for embolization. d) Final angiography after injection of 0.5 mL quick-soluble gelatin sponge particles (QS-GSPs) demonstrates resolution of the hyperstaining (white circle). The VAS pain score improved from 7 at baseline to 1 at six months.

Siemens unveils CT-guided PCI workflow system

By AuntMinnieEurope.com staff writers

The new system combines two components.

May 19, 2026

The combination of Syngo.CT Coronary Cockpit and Syngo PCI Connect gives interventional cardiologists valuable insights on morphology, plaque and lesion details and allows for strategic planning of the intervention.

Bracco's ACIST Medical Systems wins FDA clearance for Pro system

By AuntMinnie.com staff writers

The system is the next generation of ACIST's CVi automated contrast delivery technology.

May 18, 2026

Philips introduces SmartIQ coronary imaging technology for Azurion

By AuntMinnie.com staff writers

The technology reduces x-ray radiation by more than 50% compared with the lowest dose settings in Philips' ClarityIQ platform.

May 18, 2026

SIR supports genicular artery embolization for knee osteoarthritis

By AuntMinnie.com staff writers

Clinical data cites meaningful improvements with GAE.

May 12, 2026

Siemens gets FDA nod for 6 interventional imaging systems

By AuntMinnie.com staff writers

All feature the company's Optiq AI imaging chain.

May 12, 2026

Artis for interventional imaging

Radiation segmentectomy can be optimized before liver transplant

As of 2023, yttrium 90 (Y-90) radioembolization has become the most frequently used local-regional therapy in the U.S. for bridging patients with HCC to liver transplant.

May 5, 2026

Illustrations show the role of angiosome-to-tumor volume ratio (ATR) in different clinical scenarios based on tumor and treatment angiosome volume. The pale orange oval represents the tumor within the liver, and the pie-shaped region encompassed by the black lines represents the angiosome. (A) An adequate ATR (≥16) is reached when treating tumor and an accompanying appropriate volume of expendable surrounding normal parenchyma, such as a 2.5-cm tumor within a 150-mL treatment angiosome. Lower (inadequate) ATR can occur with superselective administrations, such as (B) attempting to treat a larger (4-cm) tumor within the same 150-mL angiosome, which proves suboptimal, and (C) attempting to treat the same 2.5-cm tumor within a reduced angiosome (40 mL).

FDA: Thoracic stent graft recalled after 3 deaths

By AuntMinnie.com staff writers

The FDA is advising clinicians to consider alternative stent graft options prior to using affected Relay Pro devices.

April 29, 2026

Stanford Medicine receives $3.9M ARPA-H MR lymphangiography grant

By AuntMinnie.com staff writers

Stanford will collaborate with radiologists at the University of California, Berkeley, and Imperial College London.

April 24, 2026

Andreas Loening, MD, PhD

GAE benefits may just be ‘placebo effect’

Patients who received either genicular artery embolization (GAE) or a sham procedure experienced equal pain improvements.

April 22, 2026

Contrast-enhanced T1 weSPGR images of the knee of a patient from the GAE group at the level of the suprapatellar recess. The baseline image (left) shows a marked synovial enhancement. There was no change one month after treatment (middle image) and four months after treatment (right image).

Page 1 of 190